Tandem Diabetes Earnings: What To Look For From TNDM [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
Tandem Diabetes beat analysts' revenue expectations by 1.5% last quarter, reporting revenues of $240.7 million, up 8.5% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is Tandem Diabetes a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members This quarter, analysts are expecting Tandem Diabetes's revenue to decline 3.3% year on year to $236 million, a reversal from the 31.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.34 per share. Tandem Diabetes Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tandem Diabetes has missed Wall Street's revenue estimates twice over the last two years. Looking at Tandem Diabetes's peers in t
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Hims & Hers Continues Major International Expansion With Official Entry Into Canada [Yahoo! Finance]Yahoo! Finance
- A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity [Seeking Alpha]Seeking Alpha
- Humana And Mark Cuban's Cost Plus Drugs Working On Partnership To Lower Prices [Forbes]Forbes
- Hims & Hers Health, Inc. (HIMS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 11/25/25 - Form 4
- HIMS's page on the SEC website